Midlife Heart Health: Menopause, “Normal” Fatigue & the Checkup That Matters

Episode Summary Midlife heart health is not about panic — it’s about calibration.In this American Heart Month solo episode, Rosemarie Beltz — cardiovascular perfusionist with nearly 30 years of clinical experience — breaks down what actually happens to cardiovascular risk during menopause, why “normal” fatigue may be measurable, and how high-functioning midlifers can recalibrate before a crisis.This episode explores:• The connection between menopause and heart disease • Why arterial stiffness accelerates during the menopausal transition • Coronary microvascular disease and why “normal tests” don’t always mean no problem • Why heart disease remains the leading cause of death globally • The importance of a midlife heart health checkup • GLP-1 medications and evolving cardiometabolic science • Why high performers need better data — not less careIf you are navigating midlife, perimenopause, menopause, stress, sleep shifts, or unexplained fatigue — this episode offers clarity, not fear.This conversation builds on Rosemarie’s earlier interview with interventional cardiologist Dr. Kimberly Skelding on menopause and cardiovascular risk — part of Second Opinion’s longitudinal approach to midlife health.Who This Episode Is For• Women 40+ navigating perimenopause or menopause • Midlife men avoiding preventive care • High-functioning professionals who postpone their own labs • Global listeners seeking evidence-based clarity • Anyone who has been told “your tests are normal” but still feels offKey Takeaways• Midlife is not when heart disease starts — it’s when accumulation becomes measurable. • Menopause is a vascular inflection point, not a moral failure. • Coronary microvascular disease is more common in women, especially in low-estrogen states. • A midlife heart checkup is calibration — not reassurance. • GLP-1 medications are evolving cardiometabolic medicine, but fundamentals still matter. • High performers require precision data, not dismissal.Research & Clinical Sources Referenced• CDC — Heart Disease Facts and Statistics • CDC — American Heart Month Toolkit • American Heart Association — Coronary Microvascular Disease • SWAN Study (Study of Women’s Health Across the Nation) — Arterial stiffness and menopause transition • FDA — Wegovy (semaglutide) cardiovascular risk reduction approval • AHA Journals — Vascular aging in menopauseRelated Episodes If this episode resonated, continue here:• Menopause & Heart Health: A Clinical Conversation with Dr. Kimberly Skelding A foundational discussion on vascular risk, symptoms often dismissed in women, and precision cardiology in midlife.• Midlife Fitness: Train Smarter, Not Harder Strength training, hormones, and cardiometabolic health after 40.• Sleep & the Midlife Nervous System How sleep fragmentation drives hypertension and metabolic risk.Second Opinion builds conversations longitudinally — not episodically.Global Listener NoteCardiovascular disease remains the leading cause of death worldwide.To listeners across Canada, the UK, Ireland, Australia, Europe, Africa, and Asia — midlife vascular shifts are not regional. They are physiological.Midlife women everywhere deserve better data.If this episode was valuable:• Follow or subscribe to Second Opinion • Leave a review  • Share this episode with someone navigating midlife fatigue or stress • Book your midlife heart health checkupAbout Second OpinionSecond Opinion is hosted by Rosemarie Beltz — cardiovascular perfusionist, medical journalist, and midlife health authority. Where science meets story. Where age is always your advantage.Produced from New York City. 🔗 Follow & Subscribe to never miss an episode. If you love the show, leave a review—it helps others get a second opinion!💡 Have a topic you’d love for us to cover? Reach out at www.rosemarieb.com.